Afucosylation can enable more precise assessment of allergic sensitization Berlin and Freiburg, Germany, 18 May, 2016 / B3C newswire / -- ProBioGen, a leading specialist for contract development and manufacturing of complex glycoproteins and …
Late Breaking Oral Presentation (abstract #LBA4001) on June 6 at 8:12 AM Mainz, Germany, May 17, 2016 / B3C newswire / -- Ganymed Pharmaceuticals AG, a biopharmaceutical company developing highly targeted immunotherapies against cancer, announced today …
Leading CDMO claims prestigious customer award from one of the top-20 biopharmaceutical companies Ravensburg, Germany, May 11, 2016 / B3C newswire / -- AbbVie, one of the world’s leading biopharmaceutical companies has awarded Vetter, a leading contract …
Dortmund, Germany, May 11, 2016 / B3C newswire / -- The Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH and Boehringer Ingelheim International GmbH have signed an agreement providing Boehringer Ingelheim with the option to receive the …
Garching, Germany, May 10, 2016 / B3C newswire / -- ITM Isotopen Technologien München AG, a specialized radiopharmaceutical company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), …
The $1.8 million U.S. National Cancer Institute (NCI) grant, awarded to the Medical University of South Carolina (MUSC), is intended to support a research program covering a variety of solid tumor cancers, including a Phase II study with YELIVA™ (ABC294640 …
Preliminary Data Shows That ISTH0036 was Safe and Well Tolerated at Therapeutic Dose Levels Munich, Germany, May 4, 2016 / B3C newswire / -- Isarna Therapeutics, the leader in transforming growth factor beta (TGF-ß) isoform targeted antisense therapeutics, …
London, UK, May 3, 2016 / B3C newswire/ – ORCHARD THERAPEUTICS, a clinical-stage biotechnology company with operations in London and the United States, has officially launched today with a £21-million Series A financing led by F-Prime Capital. As part of …
Effective vaccination for persons that do not respond to standard Hepatitis B vaccines Maastricht, The Netherlands, April 29, 2016 / B3C newswire / -- CyTuVax, a life science company focusing on the development of cancer and viral vaccines, today reported …
Maastricht, The Netherlands, April 29, 2016 / B3C newswire / -- Cristal Therapeutics, a privately-held life sciences company developing novel nanomedicines against cancer and other diseases, by using its patented CriPec® platform, today announced the …
Grambach and Vienna, Austria, April 27, 2016 / B3C newswire / -- VTU Technology, the Austrian protein expression expert announced today the expansion of their global technology collaboration with Boehringer Ingelheim RCV GmbH & Co. KG, a global …
Novel Enzymatic, 1-Step Site-Specific Protein Conjugation Technology for ADC Production Berlin, Germany, and Vienna, Austria, April 19, 2016 / B3C newswire / -- ProBioGen, a leading specialist for contract development and manufacturing of complex …
Clinical high-risk patients with a low-risk MammaPrint® result, including 48 percent node-positive, had five-year distant metastasis-free survival rate in excess of 94 percent, whether randomized to receive adjuvant chemotherapy or not MammaPrint could …
The FDA has confirmed, subject to final minutes of the meeting, the planned two-arm, randomized, double-blind, active comparator design of the confirmatory Phase III study with RHB-105 for the treatment of H. pylori infection, expected to be initiated in …
Krakow, Poland, April 18, 2016 / B3C newswire / -- Selvita (WSE:SLV), the largest drug discovery company in Central and Eastern Europe, has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for SEL24, …
Irvine, CA, USA and Amsterdam, the Netherlands, April 15, 2016 / B3C newswire / -- Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announced today that results from the initial analysis of the primary objective of …
Stevenage, UK, April 14, 2016 / B3C newswire / -- Apollo Therapeutics, (‘Apollo’), the investment fund focused on driving therapeutic innovation through university collaboration, has appointed Dr Richard Butt as CEO, effective from 23 May 2016. Dr Butt …
Ascenion unveils technology highlights: New approaches for the treatment of neurodegenerative disorders and glioblastoma Munich, Germany, April 13, 2016, / B3C newswire / -- On 17 May 2016, dealmakers and investors from the international biopharmaceutical …
Skokie, USA, and Ravensburg, Germany, April 12, 2016 / B3C newswire / -- The German American Chamber of Commerce® of the Midwest, Inc., (GACC Midwest) elected Susanne Resatz, Ph.D., President of Vetter Development Services USA, Chicago in March as a member …
The randomized, double-blind, 2-arm parallel group Phase II study of BEKINDA™ 12 mg is expected to enroll 120 patients suffering from diarrhea-predominant irritable bowel syndrome (IBS-D) in 12 clinical sites in the U.S. The U.S. potential market for IBS-D …
